Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.
about
Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccineIdentification of an outer membrane protein required for the transport of lipopolysaccharide to the bacterial cell surfaceCovalent antibody display--an in vitro antibody-DNA library selection systemAn OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and ToxicityFunctional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.Serogroup-specific interaction of Neisseria meningitidis capsular polysaccharide with host cell microtubules and effects on tubulin polymerizationTowards the immunoproteome of Neisseria meningitidisExpression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter.Review of meningococcal group B vaccines.Cellular and molecular biology of Neisseria meningitidis colonization and invasive diseaseHuman T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.Cellular immune responses to Neisseria meningitidis in childrenHuman opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorBProtection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccineHuman opsonins induced during meningococcal disease recognize transferrin binding protein complexes.Functional activities and immunoglobulin variable regions of human and murine monoclonal antibodies specific for the P1.7 PorA protein loop of Neisseria meningitidisImmune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate.Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from AfricaInfluence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccinesThe effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine developmentProtection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant ratsThe meningococcus tamed?Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccineImproved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.Evaluation of truncated NhhA protein as a candidate meningococcal vaccine antigen.Zinc piracy as a mechanism of Neisseria meningitidis for evasion of nutritional immunityA critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccinesImportance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccineHuman antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccineA combined vaccine approach against Vibrio cholerae and ETEC based on outer membrane vesicles.Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
P2860
Q24548670-D510C10C-0549-44D5-8CCA-613C1B98A998Q24563106-321AAECC-FDEF-4784-9671-2683CC1168F6Q24794758-10C916C8-7A3B-45CF-9466-875006CAFADAQ28607442-45201D33-1A38-45D7-82E1-35CD02ED8D24Q30175865-713E1DD3-9669-4086-A4C1-04F5C7D7C19EQ30570573-331CC32F-F410-422C-9E9D-61AB788F4880Q33468425-B120228C-59BC-44F4-B2FA-6FF5E44F34E3Q33614888-446C0322-A6F1-47A7-8939-9EFCDABC103FQ33646965-85AD1FBD-CBF4-494A-89F0-2B037A250C46Q33696949-E3F4C73C-981D-4E7B-B511-AF9E6DF51CC8Q33751297-E6A0C310-A31C-4AC6-B5E6-5F25E76F5683Q33752052-BDB40DFD-E64D-426C-BCAE-138B83E101C0Q33756300-811FE475-98F1-432B-BA60-6FCF6C5CDFC9Q33784386-18E93CCB-037A-4882-ADDB-E6167AFC7E19Q33788581-17BA6DF2-C589-4645-ADA4-8F9E8485B40BQ33867356-6E84CC0E-D798-4E3F-998C-AE65139265BFQ33867635-03EBEC25-39CA-4C5A-81E7-2619D8AD3CFAQ33946852-AFF04397-5F8C-4374-93E9-B5FEB70EF973Q34000420-B15198EA-3F5B-45D4-9B8A-D5BDC500A69AQ34002783-A4BDAAE3-CF92-4B8B-B00F-D4BA1F456E78Q34003805-CB7F787C-466A-40C8-96A8-53F040A0D9F3Q34004684-2D8CCAC4-ED8D-4020-9E08-7FE32CFA8256Q34008642-E50488E9-9EF3-4734-B312-D34E7C804A42Q34039044-D51E6F84-5595-439A-B2C8-D963F02393E5Q34131862-D6E226DC-8496-4368-9097-E34674D166C1Q34270429-6EF8DAC7-63C4-4772-B7E1-BA88A1A65DBAQ34571107-42C3E113-CAF2-432C-86A4-58077CDEEB2AQ34602010-93D2F708-421D-4850-869B-540C1EB5DF1FQ34712881-BCEC822A-619C-4C8E-8781-0C6F809918A2Q34720380-33AB2BE8-FFBB-4256-9BAB-7742C8EB85ECQ34761285-2F35BBC1-86D6-4F64-8208-CF8BBC1C21B6Q34783257-393A1917-56CB-41A2-BFE6-C02C14DDC692Q34988272-167CF7D0-3D30-4052-938C-241094855BB3Q35034259-A786417E-B719-4987-A39E-7DAFC633AED5Q35066132-83CA685B-70C0-4411-AA78-B0DF6F1A8A60Q35273041-CD645DB3-D463-4BAE-B58A-60272CCB8FE2Q35437531-C02F206B-3B51-4540-911D-7D4F2EB1EB6DQ35454550-9B28FF2B-DA44-4559-B936-29F2B6697202Q35935738-F7924B81-EF90-426A-8466-6C26792B5880Q35946901-C4827D17-BEC1-4D03-A454-2625357549C0
P2860
Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.
description
1991 nî lūn-bûn
@nan
1991 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Production, characterization a ...... group B meningococcal disease.
@ast
Production, characterization a ...... group B meningococcal disease.
@en
Production, characterization a ...... group B meningococcal disease.
@nl
type
label
Production, characterization a ...... group B meningococcal disease.
@ast
Production, characterization a ...... group B meningococcal disease.
@en
Production, characterization a ...... group B meningococcal disease.
@nl
prefLabel
Production, characterization a ...... group B meningococcal disease.
@ast
Production, characterization a ...... group B meningococcal disease.
@en
Production, characterization a ...... group B meningococcal disease.
@nl
P2093
P1433
P1476
Production, characterization a ...... group B meningococcal disease.
@en
P2093
Fredriksen JH
Frøholm LO
Lindbak AK
Rosenqvist E
P304
67-79; discussion 79-80
P577
1991-12-01T00:00:00Z